Zobrazeno 1 - 10
of 12
pro vyhledávání: '"John Nolan"'
Publikováno v:
Cancer Letters. 474:53-62
Neuroblastoma is a paediatric cancer of the sympathetic nervous system and the most common solid tumour of infancy, contributing to 15% of paediatric oncology deaths. Current therapies are not effective in the long-term treatment of almost 80% of pat
Autor:
Caroline M. Curtin, Brenton Cavanagh, Isabella Bray, Jason M. Shohet, Olga Piskareva, Ying J Tan, John Nolan, Ciara Gallagher, Ross Conlon, Harry Harvey, Suzanne F. C. Miller-Delaney, Fergal J. O'Brien, Ahmad Zaki Asraf, Larissa Deneweth, Raymond L. Stallings
Publikováno v:
Acta Biomaterialia. 70:84-97
3D scaffold-based in vitro cell culturing is a recent technological advancement in cancer research bridging the gap between conventional 2D culture and in vivo tumours. The main challenge in treating neuroblastoma, a paediatric cancer of the sympathe
Autor:
Finbarr O'Sullivan, Isabella Bray, Michael Henry, Leah Alcock, Raymond L. Stallings, John Nolan, Harry Harvey, Patrick G. Buckley, Paul Dowling, Olga Piskareva, Ross Conlon
Publikováno v:
Cancer Letters. 364:142-155
Neuroblastoma is a challenging childhood malignancy, with a very high percentage of patients relapsing following acquisition of drug resistance, thereby necessitating the identification of mechanisms of drug resistance as well as new biological targe
Autor:
Patrick G. Buckley, John Nolan, Michael Henry, Harry Harvey, Olga Piskareva, Isabella Bray, Raymond L. Stallings, Finbarr O'Sullivan, Paul Dowling, Ross Conlon, Leah Alcock
Publikováno v:
Cancer Letters. 369:428
a Cancer Genetics Group, Department of Molecular and Cellular Therapeutics, Royal College of Surgeons in Ireland, Dublin, Ireland b Children’s Research Centre, Our Lady’s Children’s Hospital, Crumlin, Dublin, Ireland c Molecular Pathology Labor
Autor:
John Nolan, E. Martin Fielden, Matthew A. Naylor, Peter O'Neill, Bridget M. Sutton, Gerald E. Adams, Ian J. Stratford
Publikováno v:
International Journal of Radiation Oncology*Biology*Physics. 29:333-337
To study the reduction of RB90740 (1), a fused pyrazine mono-N-oxide that has an oxic:hypoxic cytotoxicity ratio of10 in a range of murine and human tumor cells in vitro.Reduction of 1 has been initiated radiolytically and photochemically in aqueous
Publikováno v:
International Journal of Radiation Oncology*Biology*Physics. 22:655-659
Tritiated misonidazole (MISO) was injected intravenously (iv) into mice bearing five different tumors. At 24 hr the tumors were removed for analysis of bound MISO, and at the same time three normal tissues were removed (liver, labial gland, and esoph
Publikováno v:
British Journal of Cancer
The tritium-labelled analogues of pimonidazole and RSU 1069 were injected into mice bearing the KHT murine sarcoma which has a hypoxic cell fraction of approximately 10%. The distribution of activity at 24 h was recorded using autoradiography and mea
Publikováno v:
International Journal of Radiation Oncology*Biology*Physics. 18:347-351
The retention of labelled misonidazole (MISO) was measured in a range of normal tissues in the mouse 24 hr after the intravenous injection of [14C]MISO (ring labelled) and [3H]-MISO (side-arm labelled). For [14C]MISO the 24 hr tissue retention, in or
Publikováno v:
British Journal of Cancer
Hack and Helmy's method for the histochemical identification of NAD(P)H nitroblue tetrazolium reductase activity was employed to pinpoint reductase activity in certain cells in the mouse. High activity was observed in the following: lower airway epit
Publikováno v:
British Journal of Cancer
Scopus-Elsevier
Scopus-Elsevier
The vaso-active drug hydralazine causes a considerable increase in the cytotoxic effect of melphalan towards the KHT tumour in mice. The enhancement in response, measured as the concentration of melphalan required to achieve a given tumour response,